Myeloma Mai Yawa (MM)-02

Marasa lafiya ɗan ƙasar Italiya ya nemi magani kuma an warkar da shi daga cutar Myeloma mai yawa ta hanyar amfani da maganin CAR-T.

An gano cewa Cinty, wata mace mai shekaru 66, tana da cutar lambda light chain multiple myeloma, ISS stage I, a Italiya a watan Oktoban 2018. Bayan an yi mata tiyatar VTD sau 4, ta samu karyewa a kashi na uku na clavicle da kuma na gefe. Tana neman magani mai inganci, an yi mata dashen ƙwayoyin halitta guda biyu a watan Mayun 2019 da Nuwamba 2019, inda aka samu cikakkiyar sassauci, kuma an ci gaba da ba ta lenalidomide.

Duk da haka, a watan Agusta na 2020, wani gwajin PET/CT da aka yi ya nuna sabon lalacewar ƙashi da kuma ƙaruwa cikin sauri a cikin sarƙoƙin haske marasa jini. Binciken ƙwayoyin ƙashi ya nuna ci gaban cutar, kuma gwajin FISH ya nuna sabon rashin daidaituwar cytogenetic: t(11;14). Bayan zagaye 4 na maganin chemotherapy na DVD wanda ya fara a watan Satumba na 2020, cutar ta kasance ba a sarrafa ta ba kuma ta ci gaba da ci gaba. Duk da canzawa zuwa zagaye 3 na tsarin PCd, ciwon ƙashi ya ci gaba kuma kumburin ƙashin ƙashi ya tsananta. Bayan ta gaji da magunguna masu inganci da aka amince da su a duniya kuma an yi mata dashen ƙwayoyin halitta guda biyu, ta sami juriya ga magunguna da yawa.

Da ta samu labarin ingancin gwajin asibiti na CAR-T a cibiyarmu ta CGT ta hanyar bayanai ta yanar gizo, ta nemi biza ta isa China a watan Maris na 2021. Bayan wata guda na killacewa, an kwantar da ita a cibiyarmu ta CGT a ranar 22 ga Afrilu, 2021. Bayan gwaje-gwaje da gwaje-gwaje na cututtuka, an yi mata allurar ƙwayoyin BCMA CAR-T bayan an yi mata tiyatar maganin chemotherapy ta FC a watan Mayu na wannan shekarar. Bayan an yi mata allurar, alamunta na rayuwa sun daidaita, kuma ba ta sami wata illa mai mahimmanci ba sai dai zazzabi mai ƙarancin ƙarfi. Kumburin ƙashin bayanta ya ragu a hankali, kuma ta yi farin cikin ganin lafiyarta gaba ɗaya ta inganta.

Wata guda bayan allurar CAR-T, sakamakon gwajin Cinty ya nuna: ƙididdige furotin na fitsari na awanni 24 a 50 mg/rana, ya ragu sosai daga matakan shiga asibiti; sarƙoƙi masu haske marasa jini: FLC-κ a 4.58 mg/L da FLC-λ a 0.61 mg/L; kuma kimantawar ƙashi bai nuna wani muhimmin ƙwayoyin plasma ba. An tantance ta a asibiti a matsayin tana cikin cikakkiyar sassauci (CR).

A halin yanzu, watanni takwas bayan dawowar Cinty Italiya, ciwon baya da kumburin ƙashin ƙashi na biyu sun ɓace gaba ɗaya, kuma tana cikin koshin lafiya. Daga dubban mil daga nesa, Cinty ta nuna matuƙar godiyarta ga cibiyarmu ta CGT.

Waɗannan shari'o'i biyu na asibiti daga BIOOCUS Medical Group sun nuna cewa har ma marasa lafiya da ke da ƙarancin bayyanar BCMA ko babu myeloma da yawa za su iya samun ingantaccen tasiri tare da maganin ƙwayoyin BCMA CAR-T. Wannan yana wakiltar ci gaba a cikin maganin CAR-T don myeloma da yawa, yana kawo sabon bege ga marasa lafiya da ke da ci gaba da rikice-rikicen ƙwayoyin plasma da myeloma da yawa.